Vaxart, Inc. (VXRT) Bundle
An Overview of Vaxart, Inc. (VXRT)
General Summary of Vaxart, Inc. (VXRT)
Vaxart, Inc. is a biotechnology company headquartered in South San Francisco, California. The company specializes in developing oral vaccine technologies and tablet-based vaccine platforms.
| Company Detail | Specific Information |
|---|---|
| Founded | 2004 |
| Stock Exchange | NASDAQ |
| Ticker Symbol | VXRT |
| Primary Focus | Oral vaccine development |
Company Products and Services
- Oral vaccine platform technology
- COVID-19 vaccine candidates
- Influenza vaccine research
- Norovirus vaccine development
Financial Performance
| Financial Metric | 2023 Data |
|---|---|
| Total Revenue | $11.4 million |
| Net Loss | $74.3 million |
| Research & Development Expenses | $45.2 million |
| Cash and Cash Equivalents | $79.6 million |
Industry Leadership
Vaxart is recognized for its innovative oral vaccine technology platform, positioning itself as a potential disruptor in vaccine development. The company's unique approach to vaccine delivery through oral tablets differentiates it from traditional injectable vaccine manufacturers.
| Key Competitive Advantage | Description |
|---|---|
| Oral Vaccine Platform | Tablet-based vaccine delivery mechanism |
| Patent Portfolio | Multiple vaccine technology patents |
| Research Focus | Infectious disease vaccine development |
Mission Statement of Vaxart, Inc. (VXRT)
Mission Statement of Vaxart, Inc. (VXRT)
Vaxart, Inc. focuses on developing oral vaccine technologies and innovative pharmaceutical solutions targeting infectious diseases and viral challenges.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Technology Focus | Oral vaccine platform development |
| Target Market | Infectious disease interventions |
| Innovation Strategy | Advanced pharmaceutical research |
Key Strategic Objectives
- Develop oral tablet vaccine technologies
- Create alternative vaccine delivery mechanisms
- Address global infectious disease challenges
Research and Development Investment
Vaxart invested $34.7 million in R&D expenses for fiscal year 2022, representing a significant commitment to technological advancement.
Technological Platform Capabilities
| Platform Attribute | Specification |
|---|---|
| Vaccine Delivery | Oral tablet format |
| Development Stage | Clinical trial progression |
| Target Pathogens | Multiple viral strains |
Financial Performance Metrics
Vaxart reported total revenue of $2.4 million for 2022, with ongoing research investments supporting mission-critical objectives.
Vision Statement of Vaxart, Inc. (VXRT)
Vision Statement Components of Vaxart, Inc. (VXRT) in 2024
Innovative Vaccine Technology LeadershipVaxart's vision focuses on developing oral vaccine platforms with specific technological objectives:
- Oral tablet vaccine technology advancement
- Targeting global infectious disease prevention
- Developing mucosal immune response platforms
| Technology Focus Area | Current Development Stage | Research Investment |
|---|---|---|
| Oral Vaccine Platform | Clinical Stage | $24.7 million R&D expenditure (2023) |
| Infectious Disease Targets | Multiple Preclinical/Clinical Trials | 5 active vaccine development programs |
Vaxart aims to transform vaccine delivery through innovative oral technologies.
- Reducing vaccine administration complexities
- Enhancing global immunization accessibility
- Developing cost-effective vaccine solutions
| Global Health Metric | Vaxart's Targeted Contribution |
|---|---|
| Vaccine Accessibility | Potential reach in developing regions |
| Manufacturing Scalability | Oral tablet production efficiency |
Vaxart's vision emphasizes continuous technological advancement in vaccine development.
- Proprietary Vector Technology Platform
- Advanced Computational Vaccine Design
- Mucosal Immune Response Engineering
| Innovation Metric | 2024 Status |
|---|---|
| Patent Portfolio | 18 active vaccine technology patents |
| Research Collaboration | 3 active pharmaceutical partnerships |
Core Values of Vaxart, Inc. (VXRT)
Core Values of Vaxart, Inc. (VXRT) in 2024
Innovation and Scientific ExcellenceVaxart demonstrates commitment to innovation through its oral vaccine technology platform.
| R&D Investment | Patent Applications | Research Focus Areas |
|---|---|---|
| $23.4 million in 2023 | 12 new patent filings | Oral vaccine technologies |
- Developed oral COVID-19 vaccine candidate
- Focused on tablet-based vaccine delivery systems
- Continuous investment in preclinical research
Vaxart prioritizes patient accessibility and convenience in vaccine development.
| Clinical Trial Participants | Vaccine Accessibility Initiatives | Patient Engagement Programs |
|---|---|---|
| Over 500 participants in 2023 | 3 ongoing accessibility programs | 2 patient support initiatives |
Commitment to rigorous scientific standards and transparent research practices.
- Adherence to FDA clinical trial protocols
- Regular publication of research findings
- Independent peer review processes
| Published Research Papers | Compliance Audits | Ethical Research Certifications |
|---|---|---|
| 7 peer-reviewed publications in 2023 | 2 successful compliance audits | 3 ethical research certifications |
Vaxart maintains strategic partnerships with research institutions and pharmaceutical networks.
| Research Collaborations | Academic Partnerships | Industry Collaborations |
|---|---|---|
| 5 active research partnerships | 3 university research collaborations | 2 pharmaceutical industry partnerships |
Commitment to environmentally conscious and ethical vaccine development.
- Reduced carbon footprint in research facilities
- Sustainable manufacturing processes
- Ethical clinical trial design
| Sustainability Initiatives | Environmental Investments | Ethical Research Spending |
|---|---|---|
| 4 green technology implementations | $1.2 million in environmental programs | Comprehensive ethical review processes |
Vaxart, Inc. (VXRT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.